|
1
|
Fidler MM, Gupta S, Soerjomataram I,
Ferlay J, Steliarova-Foucher E and Bray F: Cancer incidence and
mortality among young adults aged 20-39 years worldwide in 2012: A
population-based study. Lancet Oncol. 18:1579–1589. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Forman D, Bray F, Brewster DH, Gombe MC,
Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay
J (eds): Cancer incidence in five continents. Vol. 10 (electronic
version). IARC Scientific Publications No. 164. International
Agency for Research on Cancer, Lyon, 2013.
|
|
3
|
Parada H Jr, Sun X, Tse CK, Olshan AF and
Troester MA: Lifestyle patterns and survival following breast
cancer in the carolina breast cancer study. Epidemiology. 30:83–92.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Alkabban FM and Ferguson T: Breast cancer.
In: StatPearls. StatPearls Publishing, Treasure Island (FL),
2020.
|
|
5
|
Imsamran W, Chaiwerawattana A, Wiangnon S,
Pongnikorn D, Suwanrungrung K, Sangrajrang S and Buasom R: Cancer
in Thailand. Vol. 8, 2010-2012. New Thammada Press (Thailand) Co.,
Ltd., 2015.
|
|
6
|
Park S, Koo JS, Kim MS, Park HS, Lee JS,
Lee JS, Kim SI and Park BW: Characteristics and outcomes according
to molecular subtypes of breast cancer as classified by a panel of
four biomarkers using immunohistochemistry. Breast. 21:50–57.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Grey HM, Kubo RT, Colon SM, Poulik MD,
Cresswell P, Springer T, Turner M and Strominger JL: The small
subunit of HL-A antigens is beta 2-microglobulin. J Exp Med.
138:1608–1612. 1973.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cresswell P, Springer T, Strominger JL,
Turner MJ, Grey HM and Kubo RT: Immunological identity of the small
subunit of HL-A antigens and beta2-microglobulin and its turnover
on the cell membrane. Proc Natl Acad Sci USA. 71:2123–2127.
1974.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Karlsson FA, Groth T, Sege K, Wibell L and
Peterson PA: Turnover in humans of beta 2-microglobulin: The
constant chain of HLA-antigens. Eur J Clin Invest. 10:293–300.
1980.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Karlsson FA, Wibell L and Evrin PE: Beta
2-microglobulin in clinical medicine. Scand J Clin Lab Invest
Suppl. 154:27–37. 1980.PubMed/NCBI
|
|
11
|
Hofstra JM, Deegens JK, Willems HL and
Wetzels JF: Beta-2-microglobulin is superior to
N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic
membranous nephropathy. Nephrol Dial Transplant. 23:2546–2551.
2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nozue T, Michishita I and Mizuguchi I:
Predictive value of serum cystatin C, β2-microglobulin, and urinary
liver-type fatty acid-binding protein on the development of
contrast-induced nephropathy. Cardiovasc Interv Ther. 25:85–90.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Diem H, Fateh-Moghadam A and Lamerz R:
Prognostic factors in multiple myeloma: Role of beta
2-microglobulin and thymidine kinase. Clin Investig. 71:918–923.
1993.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Musarurwa C and Matarira HT:
Beta-2-microglobulin in multiple myeloma. Cent Afr J Med. 50:19–20.
2004.PubMed/NCBI
|
|
15
|
Vassilakopoulos TP, Nadali G, Angelopoulou
MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C,
Kokoris SI, Dimitriadou EM, Calpadaki C, et al:
Beta(2)-microglobulin in Hodgkin's lymphoma: Prognostic
significance in patients treated with ABVD or equivalent regimens.
J BUON. 10:59–69. 2005.PubMed/NCBI
|
|
16
|
Berrebi A, Bassous L, Haran M, Shtalrid M
and Shvidel L: The significance of elevated beta 2-microglobulin
(b2-m) in chronic lymphocytic leukemia (CLL): Evidence of in vitro
secretion following activation of CLL cells. Leuk Res.
34:e248–e249. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vassilakopoulos TP, Nadali G, Angelopoulou
MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Karkantaris C,
Kokoris SI, Kyrtsonis MC, Tsaftaridis P, et al: The prognostic
significance of beta(2)-microglobulin in patients with Hodgkin's
lymphoma. Haematologica. 87:701–708. 2002.PubMed/NCBI
|
|
18
|
Tsimberidou AM, Kantarjian HM, Wen S,
O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M,
Freireich EJ, et al: The prognostic significance of serum beta2
microglobulin levels in acute myeloid leukemia and prognostic
scores predicting survival: Analysis of 1,180 patients. Clin Cancer
Res. 14:721–730. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Durie BG, Stock-Novack D, Salmon SE,
Finley P, Beckord J, Crowley J and Coltman CA: Prognostic value of
pretreatment serum beta 2 microglobulin in myeloma: A Southwest
oncology group study. Blood. 75:823–830. 1990.PubMed/NCBI
|
|
20
|
Papaioannou D, Geggie P and Klassen J:
Study of serum beta-2 microglobulin levels in breast cancer
patients. Clin Chim Acta. 99:37–41. 1979.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Klein B, Levin I, Kfir B, Mishaeli M,
Shapira J and Klein T: The significance of soluble interleukin-2,
soluble interleukin-2 receptors, soluble ICAM-1 and beta
2-microglobulin in breast cancer patients. Tumour Biol. 16:290–296.
1995.PubMed/NCBI
|
|
22
|
Li K, Du H, Lian X, Yang S, Chai D, Wang
C, Yang R and Chen X: Characterization of β2-microglobulin
expression in different types of breast cancer. BMC Cancer.
14(750)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chai D, Li K, Du H, Yang S, Yang R, Xu Y
and Lian X: β2-microglobulin has a different regulatory molecular
mechanism between ER+ and ER- breast cancer
with HER2. BMC Cancer. 19(223)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tsuda H, Hirohashi S, Higuchi K and
Shimosato Y: Beta-2-microglobulin expression in relation to
amplification of oncogenes and prognosis in breast carcinoma.
Histopathology. 16:500–502. 1990.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhou B, Xu L, Ye J, Xin L, Duan X and Liu
Y: The prognostic value of the 8th edition of the American joint
committee on cancer (AJCC) staging system in HER2-enriched subtype
breast cancer, a retrospective analysis. Anticancer Res.
37:4615–4621. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Khaled H, Gamal H, Lotayef M, Knauer M and
Thürliman B: The St. Gallen international expert consensus
conference on the primary therapy of early breast cancer 2017:
Egyptian view. Breast Cancer Res Treat. 172:545–550.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wibell L: The serum level and urinary
excretion of beta2-microglobulin in health and renal disease.
Pathol Biol (Paris). 26:295–301. 1978.PubMed/NCBI
|
|
28
|
Karlsson FA, Dahlberg PA, Venge P and
Roxin LE: Serum myoglobin in thyroid disease. Acta Endocrinol
(Copenh). 94:184–187. 1980.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shi C, Zhu Y, Su Y, Chung LW and Cheng T:
Beta2-microglobulin: Emerging as a promising cancer therapeutic
target. Drug Discov Today. 14:25–30. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Teasdale C, Mander AM, Fifield R, Keyser
JW, Newcombe RG and Hughes LE: Serum beta2-microglobulin in
controls and cancer patients. Clin Chim Acta. 78:135–143.
1977.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Petekkaya I, Aksoy S, Roach EC, Okoh AK,
Gecmez G, Gezgen G, Isler DC, Dogan E, Babacan T, Sarici F, et al:
Impact of inflammatory markers on the prognosis of patients with
operable breast cancer. J BUON. 19:673–680. 2014.PubMed/NCBI
|
|
32
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Josson S, Nomura T, Lin JT, Huang WC, Wu
D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M and Chung LW:
β2-Microglobulin induces epithelial to mesenchymal transition and
confers cancer lethality and bone metastasis in human cancer cells.
Cancer Res. 71:2600–2610. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen CH, Su CY, Chien CY, Huang CC, Chuang
HC, Fang FM, Huang HY, Chen CM and Chiou SJ: Overexpression of
beta2-microglobulin is associated with poor survival in patients
with oral cavity squamous cell carcinoma and contributes to oral
cancer cell migration and invasion. Br J Cancer. 99:1453–1461.
2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Petekkaya I, Unlu O, Roach EC, Gecmez G,
Okoh AK, Babacan T, Sarici F, Keskin O, Arslan C, Petekkaya E, et
al: Prognostic role of inflammatory biomarkers in metastatic breast
cancer. J BUON. 22:614–622. 2017.PubMed/NCBI
|
